The use of GLP-1 medications during training, deployments, or operational platforms might not be authorized
This comprehensive approach is what the FDA and medical guidelines call for, but rarely operationalize
however, not all patients are prescribed weight loss medications
Microdosing GLP-1 medication is not FDA-approved and is used as an off-label practice, which is not supported by any clinical trials
Rushing through titration dramatically increases side effect severity
Novo Nordisk previously claimed to have been alarmed by "reports of medical spas, weight loss clinics, pharmacies, and other companies" selling compounded semaglutide to patients on the grounds that they "do not have the same safety, quality, and effectiveness assurances as Novo Nordisk's FDA-approved drugs." Compounding pharmacies are mostly regulated at the state level by boards of pharmacy